Teriparatide
- Generic Name
- Teriparatide
- Brand Names
- Forsteo, Forteo, Movymia, Kauliv, Sondelbay, Teriparatide Sun, Terrosa, Livogiva
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 52232-67-4
- Unique Ingredient Identifier
- 10T9CSU89I
- Background
Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic th...
- Indication
Teriparatide is indicated:
- Associated Conditions
- Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Primary Osteoporosis
- Associated Therapies
- -
Weekly vs Daily Teriparatide Therapy in Severe Postmenopausal Osteoporosis
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2014-04-16
- Target Recruit Count
- 20
- Registration Number
- NCT01760798
- Locations
- 🇮🇳
PGIMER, Chandigarh, UT, India
Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2012-12-20
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 69
- Registration Number
- NCT01753856
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sainte-Foy, Quebec, Canada
Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo
- Conditions
- Interventions
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 90
- Registration Number
- NCT01734824
- Locations
- 🇦🇹
Medical University Vienna - St. Vincent Hospital, Vienna, Austria
VERtebral Fracture Treatment Comparisons in Osteoporotic Women
- Conditions
- Interventions
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1366
- Registration Number
- NCT01709110
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain
Fracture (FX) Improvement With Teriparatide: FiX-IT Study
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Susan L. Greenspan
- Target Recruit Count
- 13
- Registration Number
- NCT01705587
- Locations
- 🇺🇸
University of Pittsburgh, Osteoporosis Prevention & Treatment Center, Pittsburgh, Pennsylvania, United States
The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
- Conditions
- Interventions
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 9
- Registration Number
- NCT01679080
- Locations
- 🇩🇰
Department of Endocrinology M, Odense, Denmark
🇩🇰Department of endocrinology, Hvidovre, Denmark
🇩🇰Osteoporosis clinic; department of endocrinology and metabolism, Aarhus, Aarhus C, Denmark
Stem Cell Recruitment in Osteoporosis Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 55
- Registration Number
- NCT01656629
- Locations
- 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 31
- Registration Number
- NCT01611571
- Locations
- 🇺🇸
Columbia University Medical Center, Harkness Pavilion, New York City, New York, United States
Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass
- First Posted Date
- 2012-05-23
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- Azelon Pharmaceuticals
- Target Recruit Count
- 130
- Registration Number
- NCT01604057
Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 125
- Registration Number
- NCT01535027
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.